Global Hypodermic Needles Market
1. An Outline of the Global Hypodermic Needles Market
1.1. Market Definition and Segmentation
1.2. Study Assumptions and Abbreviations
2. Research Methodology & Approach
2.1. Primary Research
2.2. Secondary Research
2.3. Data Triangulation
2.4. SPSS Methodology
3. Executive Summary
4. Growth Drivers
5. Major Roadblocks
6. Opportunities
7. Prevalent Trends
8. Government Regulation
9. Growth Outlook
10. Competitive White Space Analysis – Identifying Untapped Market Gaps
11. Risk Overview
12. SWOT
13. Technological Advancement
14. Technology Maturity Matrix for the Hypodermic Needles Market: Recent News
15. Regional Demand
16. Global Hypodermic Needles by Geography – Strategic Comparative Analysis
17. Strategic Segment Analysis: Hypodermic Needles Demand Landscape
18. Hypodermic Needles Demand Trends Driven by increasing demand for injectable therapies, rising geriatric population worldwide, and expanding immunization and vaccination coverage. (2027-2036)
19. Root Cause Analysis (RCA) for discovering problems of the Hypodermic Needles Market
20. Porter Five Forces
21. PESTLE
22. Comparative Positioning
23. Global Hypodermic Needles – Key Player Analysis (2036)
24. Competitive Landscape: Key Suppliers/Players
25. Competitive Model: A Detailed Inside View for Investors
26. Company Market Share, 2036 (%)
26.1. B. Braun SE
26.2. BD
26.3. Cardinal Health
26.4. Connecticut Hypodermics Inc.
26.5. Exelint International, Co.
26.6. Henke Sass Wolf
26.7. Hi-Tech Syringes
26.8. ICU Medical, Inc.
26.9. Nipro Europe Group Companies
26.10. Retractable Technologies, Inc.
26.11. Terumo Medical Corporation.
27. Global Hypodermic Needles Market Outlook
27.1. Market Overview
27.1.1. Market Revenue by Value (USD Million), by Volume (USD Units), and Compound Annual Growth Rate (CAGR)
27.2. Hypodermic Needles Market Segmentation Analysis (2027-2036)
27.2.1. By Product Type
27.2.1.1. Safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
27.2.1.1.1. Retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
27.2.1.1.2. Non-retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
27.2.1.2. Non-safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
27.2.2. By Application
27.2.2.1. Drug Delivery, Market Value (USD Million), and CAGR, 2027-2036F
27.2.2.2. Vaccination, Market Value (USD Million), and CAGR, 2027-2036F
27.2.2.3. Blood Specimen Collection, Market Value (USD Million), and CAGR, 2027-2036F
27.2.2.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
27.2.3. By End user
27.2.3.1. Hospitals and Clinics, Market Value (USD Million), and CAGR, 2027-2036F
27.2.3.2. Cancer Treatment Centers, Market Value (USD Million), and CAGR, 2027-2036F
27.2.3.3. Dermatology Clinics, Market Value (USD Million), and CAGR, 2027-2036F
27.2.3.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
27.2.4. Regional Synopsis, Value (USD Million), 2027-2036
27.2.4.1. North America Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
27.2.4.2. Europe Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
27.2.4.3. Asia Pacific, excluding Japan Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
27.2.4.4. Latin America Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
27.2.4.5. Middle East and Africa Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
28. North America Market
28.1. Overview
28.1.1. Market Value (USD Million), Current and Future Projections, 2027-2036
28.1.2. Increment $ Opportunity Assessment, 2027-2036
28.2. Segmentation (USD Million), 2027-2036, By
28.2.1. By Product Type
28.2.1.1. Safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
28.2.1.1.1. Retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
28.2.1.1.2. Non-retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
28.2.1.2. Non-safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
28.2.2. By Application
28.2.2.1. Drug Delivery, Market Value (USD Million), and CAGR, 2027-2036F
28.2.2.2. Vaccination, Market Value (USD Million), and CAGR, 2027-2036F
28.2.2.3. Blood Specimen Collection, Market Value (USD Million), and CAGR, 2027-2036F
28.2.2.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
28.2.3. By End user
28.2.3.1. Hospitals and Clinics, Market Value (USD Million), and CAGR, 2027-2036F
28.2.3.2. Cancer Treatment Centers, Market Value (USD Million), and CAGR, 2027-2036F
28.2.3.3. Dermatology Clinics, Market Value (USD Million), and CAGR, 2027-2036F
28.2.3.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
28.2.4. Country Level Analysis, Value (USD Million)
28.2.4.1. U.S. Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
28.2.4.2. Canada Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
29. Europe Market
29.1. Overview
29.1.1. Market Value (USD Million), Current and Future Projections, 2027-2036
29.1.2. Increment $ Opportunity Assessment, 2027-2036
29.2. Segmentation (USD Million), 2027-2036, By
29.2.1. By Product Type
29.2.1.1. Safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
29.2.1.1.1. Retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
29.2.1.1.2. Non-retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
29.2.1.2. Non-safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
29.2.2. By Application
29.2.2.1. Drug Delivery, Market Value (USD Million), and CAGR, 2027-2036F
29.2.2.2. Vaccination, Market Value (USD Million), and CAGR, 2027-2036F
29.2.2.3. Blood Specimen Collection, Market Value (USD Million), and CAGR, 2027-2036F
29.2.2.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
29.2.3. By End user
29.2.3.1. Hospitals and Clinics, Market Value (USD Million), and CAGR, 2027-2036F
29.2.3.2. Cancer Treatment Centers, Market Value (USD Million), and CAGR, 2027-2036F
29.2.3.3. Dermatology Clinics, Market Value (USD Million), and CAGR, 2027-2036F
29.2.3.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
29.2.4. Country Level Analysis, Value (USD Million)
29.2.4.1. UK Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
29.2.4.2. Germany Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
29.2.4.3. France Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
29.2.4.4. Italy Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
29.2.4.5. Spain Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
29.2.4.6. Netherlands Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
29.2.4.7. Russia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
29.2.4.8. Switzerland Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
29.2.4.9. Poland Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
29.2.4.10. Belgium Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
29.2.4.11. Rest of Europe Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30. Asia Pacific Market
30.1. Overview
30.1.1. Market Value (USD Million), Current and Future Projections, 2027-2036
30.1.2. Increment $ Opportunity Assessment, 2027-2036
30.2. Segmentation (USD Million), 2027-2036, By
30.2.1. By Product Type
30.2.1.1. Safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
30.2.1.1.1. Retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
30.2.1.1.2. Non-retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
30.2.1.2. Non-safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
30.2.2. By Application
30.2.2.1. Drug Delivery, Market Value (USD Million), and CAGR, 2027-2036F
30.2.2.2. Vaccination, Market Value (USD Million), and CAGR, 2027-2036F
30.2.2.3. Blood Specimen Collection, Market Value (USD Million), and CAGR, 2027-2036F
30.2.2.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
30.2.3. By End user
30.2.3.1. Hospitals and Clinics, Market Value (USD Million), and CAGR, 2027-2036F
30.2.3.2. Cancer Treatment Centers, Market Value (USD Million), and CAGR, 2027-2036F
30.2.3.3. Dermatology Clinics, Market Value (USD Million), and CAGR, 2027-2036F
30.2.3.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
30.2.4. Country Level Analysis, Value (USD Million)
30.2.4.1. China Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30.2.4.2. Japan Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30.2.4.3. India Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30.2.4.4. South Korea Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30.2.4.5. Australia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30.2.4.6. Indonesia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30.2.4.7. Malaysia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30.2.4.8. Vietnam Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30.2.4.9. Thailand Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30.2.4.10. Singapore Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30.2.4.11. New Zealand Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
30.2.4.12. Rest of Asia Pacific Excluding Japan Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
31. Latin America Market
31.1. Overview
31.1.1. Market Value (USD Million), Current and Future Projections, 2027-2036
31.1.2. Increment $ Opportunity Assessment, 2027-2036
31.1.3. Year-on-Year Growth Forecast (%)
31.2. Segmentation (USD Million), 2027-2036, By
31.2.1. By Product Type
31.2.1.1. Safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
31.2.1.1.1. Retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
31.2.1.1.2. Non-retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
31.2.1.2. Non-safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
31.2.2. By Application
31.2.2.1. Drug Delivery, Market Value (USD Million), and CAGR, 2027-2036F
31.2.2.2. Vaccination, Market Value (USD Million), and CAGR, 2027-2036F
31.2.2.3. Blood Specimen Collection, Market Value (USD Million), and CAGR, 2027-2036F
31.2.2.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
31.2.3. By End user
31.2.3.1. Hospitals and Clinics, Market Value (USD Million), and CAGR, 2027-2036F
31.2.3.2. Cancer Treatment Centers, Market Value (USD Million), and CAGR, 2027-2036F
31.2.3.3. Dermatology Clinics, Market Value (USD Million), and CAGR, 2027-2036F
31.2.3.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
31.2.4. Country Level Analysis, Value (USD Million)
31.2.4.1. Brazil Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
31.2.4.2. Argentina Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
31.2.4.3. Mexico Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
31.2.4.4. Rest of Latin America Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
32. Middle East & Africa Market
32.1. Overview
32.1.1. Market Value (USD Million), Current and Future Projections, 2027-2036
32.1.2. Increment $ Opportunity Assessment, 2027-2036
32.1.3. Year-on-Year Growth Forecast (%)
32.2. Segmentation (USD Million), 2027-2036, By
32.2.1. By Product Type
32.2.1.1. Safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
32.2.1.1.1. Retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
32.2.1.1.2. Non-retractable Needles, Market Value (USD Million), and CAGR, 2027-2036F
32.2.1.2. Non-safety Hypodermic Needles, Market Value (USD Million), and CAGR, 2027-2036F
32.2.2. By Application
32.2.2.1. Drug Delivery, Market Value (USD Million), and CAGR, 2027-2036F
32.2.2.2. Vaccination, Market Value (USD Million), and CAGR, 2027-2036F
32.2.2.3. Blood Specimen Collection, Market Value (USD Million), and CAGR, 2027-2036F
32.2.2.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
32.2.3. By End user
32.2.3.1. Hospitals and Clinics, Market Value (USD Million), and CAGR, 2027-2036F
32.2.3.2. Cancer Treatment Centers, Market Value (USD Million), and CAGR, 2027-2036F
32.2.3.3. Dermatology Clinics, Market Value (USD Million), and CAGR, 2027-2036F
32.2.3.4. Others, Market Value (USD Million), and CAGR, 2027-2036F
32.2.4. Country Level Analysis, Value (USD Million)
32.2.4.1. Saudi Arabia Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
32.2.4.2. UAE Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
32.2.4.3. Israel Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
32.2.4.4. Qatar Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
32.2.4.5. Kuwait Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
32.2.4.6. Oman Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
32.2.4.7. South Africa Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
32.2.4.8. Rest of Middle East & Africa Market Value (USD Million) and CAGR & Y-o-Y Growth Trend, 2027-2036F
33. Global Economic Scenario
33.1. World Economic Outlook
34. About Research Nester
34.1. Our Global Clientele
34.2. We Serve Clients Across World
Hypodermic Needles Market Outlook:
Hypodermic Needles Market size was valued at USD 5.01 billion in 2026 and is anticipated to reach USD 8.93 billion by the end of 2036, expanding at around 6.01% CAGR during the forecast period, i.e., 2027-2036. In 2027, the industry size of hypodermic needles is assessed at USD 5.28 billion.
The rising prevalence of Hepatitis B and Hepatitis C is directly propelling the sales of hypodermic needles. The World Health Organization (WHO) disclosed that about 47 million people worldwide are living with chronic hepatitis C, and around 900,000 new cases are reported each year. Direct-acting antiviral medicines are expected to cure more than 95% of patients, but many people still do not get tested or treated.
Most early infections show no symptoms and are not usually severe. About 30% of infected people clear the virus on their own within six months, while the rest may develop long-term infection. Among those with chronic hepatitis C, 15% to 30% may develop cirrhosis within 20 years. The increasing diagnosis and treatment needs fuel the demand for advanced hypodermic needles.
Hepatitis C Virus - Chronic Infections by WHO 2026 Data
|
Region |
Number of People Chronically Infected |
Notes |
|
Eastern Mediterranean |
12 million |
Highest burden |
|
South-East Asia |
9 million |
- |
|
Europe |
9 million |
- |
|
Western Pacific |
7 million |
- |
|
Africa |
8 million |
- |
|
Region of the Americas |
5 million |
- |
Source: WHO
Cost-Effectiveness of Harm Reduction Strategies for Hepatitis C Prevention among Opioid Injection Drug Users (Public Payer Perspective, 2019 USD)
|
Strategy |
Incremental Cost Savings per HCV Case Avoided (per 100 IDUs) vs. No Intervention |
ICER (Incremental Cost-Effectiveness Ratio) |
|
SSP + MOUD Combination |
USD 347,573 |
USD 4,699 (vs. SSP alone) |
|
SSP alone |
USDc363,821 |
- |
|
MOUD alone |
USD 317,428 |
- |
Source: National Center for Biotechnology Information (NCBI)
Key Summary Points (for reference):
- Syringe service programs (SSPs) alone showed the highest cost savings per HCV case avoided.
- SSP + medications for opioid use disorder (MOUD) and SSP alone both dominate MOUD alone and no intervention.
- Additional cost of choosing SSP + MOUD over SSP alone: USD 4,699 per additional HCV case avoided.
Key Hypodermic Needles Market Insights Summary:
Regional Insights:
- In the hypodermic needles market, North America is anticipated to account for 34.8% market share by 2036, bolstered by advanced healthcare infrastructure, high healthcare expenditure, and expanding government-backed vaccination programs
- Asia Pacific is poised to witness the fastest growth through 2036, fueled by expanding healthcare infrastructure, a large aging population, and increasing government-led immunization initiatives
- The U.S. hypodermic needles market is expected to increase at a CAGR of 5.46% from 2027 to 2036, mainly owing to the robust investments in advanced medical technologies
- Japan is projected to capture nearly 11.3% of the Asia Pacific hypodermic needles market share by 2036, supported by continuous technological advancements and a rise in cancer cases
Segment Insights:
- In the hypodermic needles market, the safety hypodermic needles segment is expected to capture 59.2% market share by 2036, attributed to rising demand for safety needles in hospitals and clinics and growing awareness of safe and hygienic healthcare practices
- The drug delivery segment is projected to secure 49.3% market share by 2036, reinforced by the rising prevalence of chronic diseases, increasing adoption of injectable drugs, and growing demand for self-administration of medications
Key Growth Trends:
- Growing prevalence of chronic diseases
- Expansion of healthcare infrastructure
Major Challenges:
- Environmental concerns
- Expansion of counterfeit and low-quality needle products
Key Players: B. Braun SE (Germany),BD (U.S.),Cardinal Health (U.S.),Connecticut Hypodermics Inc. (U.S.),Exelint International, Co. (U.S.),Henke Sass Wolf (Germany),Hi-Tech Syringes (India),ICU Medical, Inc. (U.S.),Nipro Europe Group Companies (Belgium),Retractable Technologies, Inc. (U.S.),Terumo Medical Corporation (Japan).
Global Hypodermic Needles Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2026 Market Size: USD 5.01 billion
- 2027 Market Size: USD 5.28 billion
- Projected Market Size: USD 8.93 billion by 2036
- Growth Forecasts: 6.01% CAGR (2027-2036)
Key Regional Dynamics:
- Largest Region: North America (34.8% share by 2036)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, China, Germany, Japan, United Kingdom
- Emerging Countries: India, South Korea, Brazil, Indonesia, Vietnam
Last updated on : 16 July, 2026
Hypodermic Needles Market - Growth Drivers and Challenges
Growth Drivers
- Growing prevalence of chronic diseases: The growing global burden of chronic diseases is propelling the sales of hypodermic needles. Conditions such as diabetes, cardiovascular diseases, and hormonal disorders often require frequent or long-term injectable therapies, creating continuous demand for hypodermic needles. By 2050, the International Diabetes Federation expects about 1 in 8 adults, or roughly 853 million people, to be living with diabetes, which would be a 46% rise. More than 90% of people with diabetes are expected to have type 2 diabetes, which is linked to social, economic, environmental, demographic, and genetic factors. Thus, as chronic disease prevalence continues to rise worldwide, the demand for hypodermic needles is set to boom.
- Expansion of healthcare infrastructure: The expansion and modernization of healthcare infrastructure worldwide are significantly contributing to the increasing demand for hypodermic needles. The rise in public-private investments is propelling the trade of medical devices and equipment, including hypodermic needles. In July 2026, Skanska USA said it had finished the first phase of the USD 400 million renovation and expansion of the emergency room at Jackson Memorial Hospital in Miami, Florida. The project is part of a larger multi-stage upgrade at one of the country’s major public healthcare systems. Thus, as global healthcare infrastructure continues to improve, the trade of hypodermic needles is expected to increase.
- Increasing number of surgical and medical procedures: The rising number of surgical procedures and hospital admissions is driving the demand for hypodermic needles across healthcare settings. The increasing prevalence of chronic diseases and an aging population are boosting the application of surgical technologies, including hypodermic needles. The growth in emergency care and trauma management is also contributing to the overall hypodermic needles market growth.
Challenges
- Environmental concerns: The disposal of used hypodermic needles and plastic-based medical sharps is likely to create environmental challenges. The improper disposal of these needles is likely to contribute to plastic pollution, landfill accumulation, and accidental sharps injuries, limiting their overall sales. The use of sustainable and disposable materials is likely to aid key players in overcoming this issue.
- Expansion of counterfeit and low-quality needle products: The presence of counterfeit and low-quality hypodermic needles is hampering the trade of hypodermic needles. The proliferation of counterfeit products, particularly in price-sensitive markets, lowers the adoption of branded products. Digital marketing and strict regulatory frameworks are expected to aid leading companies in overcoming this challenge.
Hypodermic Needles Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2026 |
|
Forecast Year |
2027-2036 |
|
CAGR |
6.01% |
|
Base Year Market Size (2026) |
USD 5.01 billion |
|
Forecast Year Market Size (2036) |
USD 8.93 billion |
|
Regional Scope |
|
Hypodermic Needles Market Segmentation:
Product Type Segment Analysis
The global hypodermic needles market is segmented and analyzed for demand and supply by product type into safety hypodermic needles and non-safety hypodermic needles. Out of these, the safety hypodermic needles segment is estimated to gain the largest market share of about 59.2% by the year 2036. The growth of the segment can be attributed to the increasing demand for safety needles in hospitals and clinics, as well as the growing awareness among healthcare professionals about the need for safe and hygienic practices, which is driving the growth of this segment. Additionally, the rising incidence of needle-stick injuries has resulted in the adoption of safety needles to reduce the risk and ensure patient safety. In Accordance with the CDC, the number of injuries caused by contaminated needles and other sharp devices among hospital-based healthcare personnel exceeds 385,000 injuries every year. This equates to over 1,000 injuries a day.
Application Segment Analysis
The global hypodermic needles market is segmented and analyzed for demand and supply by application into drug delivery, vaccination, blood specimen collection, and others. Out of these, the drug delivery segment is estimated to gain a significant market share of about 49.3% during the study period. The growth of the segment is attributed to the rising prevalence of chronic diseases, increasing adoption of injectable drugs, and growing demand for self-administration of drugs by patients, which is encouraging the manufacturers to focus on product innovation and development. Additionally, technological advancements in injection devices are also expected to drive the drug delivery segment growth. Furthermore, the presence of a wide range of advanced injection devices such as auto-injectors, pen injectors, and jet injectors is expected to contribute to segment growth.
End user Segment Analysis
The hospitals and clinics segment is projected to account for 71.6% of the global hypodermic needles market share through 2036. The extensive and continuous requirement for injection-based treatments, diagnostic procedures, and emergency medical care drives the segmental growth. On average across OECD countries, there were 128 acute care hospital discharges for every 1,000 people in 2023. These healthcare facilities perform a high volume of procedures, making hypodermic needles an essential medical consumable. Thus, the increasing number of hospital admissions and outpatient visits drives the trade of hypodermic needles.
Our in-depth analysis of the hypodermic needles market includes the following segments:
|
Segments |
Subsegments |
|
Product Type |
|
|
Application
|
|
|
End user |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Hypodermic Needles Market - Regional Analysis
North America Market Insights
North America is projected to capture 34.8% of the global hypodermic needles market through 2036. The market growth is expected to be supported by its advanced healthcare infrastructure and high healthcare expenditure. The widespread adoption of injectable therapies also contributes to the increasing sales of hypodermic needles. Government-supported vaccination programs and seasonal immunization campaigns are further opening high-earning opportunities for hypodermic needle manufacturers.
The U.S. hypodermic needles market is estimated to reach USD 2,588.15 million by 2036. The country witnesses a consistent demand for hypodermic needles due to the growing prevalence of chronic diseases. The Centers for Disease Control and Prevention (CDC) estimates that in 2023, about 40.1 million people in the U.S. had diabetes, whether diagnosed or not. This was about 12.0% of the U.S. population. The expanding use of biologics, insulin, and specialty pharmaceuticals further strengthens the need for high-quality hypodermic needles.
Canada’s market for hypodermic needles is anticipated to expand at a CAGR of 6.52% from 2027 to 2036. The hypodermic needles market growth is supported by its publicly funded healthcare system and increasing chronic disease burden. The strong emphasis on patient safety drives the sales of hypodermic needles. As per the 2023 to 2024 data from the Canadian Chronic Disease Surveillance System, 8.2% of adults in Canada had diagnosed ischemic heart disease. The country's expanding elderly population and rising prevalence of cardiovascular diseases are increasing the demand for injectable solutions.
Asia Pacific Market Insights
Asia Pacific is estimated to hold 29.5% of the global hypodermic needles market through 2036. The market is expected to witness robust growth, driven by expanding healthcare infrastructure and a large and aging population. The increasing burden of chronic and infectious diseases is also contributing to the increasing sales of hypodermic needles. The government-led immunization programs and national vaccination initiatives also drive the trade in hypodermic needles.
China’s market for hypodermic needles was estimated at USD 425.50 million in 2026. The country’s vast population and expanding healthcare system are fueling the demand for hypodermic needles. The rapidly growing pharmaceutical industry is also contributing to the hypodermic needles market growth. The increasing prevalence of chronic diseases, including diabetes, hypertension, and cardiovascular disorders, is substantially increasing demand for hypodermic needles. The International Diabetes Federation reveals that the prevalence of diabetes in China is nearly 11.9%.
Japan is estimated to increase from USD 202.55 million in 2027 to USD 298.97 million by 2036. The high healthcare standards and swiftly increasing aging population are propelling the sales of hypodermic needles. The increasing prevalence of chronic diseases such as diabetes, cancer, osteoporosis, and cardiovascular disorders is boosting the trade of hypodermic needles. The Foundation for Promotion of Cancer Research reveals that Japan had an estimated 979,300 new cancer cases in 2024, including about 558,300 among men and 421,000 among women.
Japan's advanced healthcare systems are also contributing to the increasing sales of hypodermic needles. Technological innovations are set to fuel the adoption of premium disposable and safety-engineered hypodermic needles. The public-private hospital-led immunization programs and national vaccination initiatives are directly fueling the sales of hypodermic needles.
Cancer Case Statistics 2024
|
Male |
Female |
||
|
Cancer |
Share |
Cancer |
Share |
|
Prostate |
16% |
Breast |
22% |
|
Colon/Rectum |
15% |
Colon/Rectum |
16% |
|
Lung |
15% |
Lung |
10% |
|
Stomach |
14% |
Stomach |
9% |
|
Liver |
4% |
Uterus |
7% |
Source: Foundation for Promotion of Cancer Research
Europe Market Insights
Europe is projected to account for 25.9% of the global hypodermic needles by the end of the forecast period. The hypodermic needles market growth is supported by its well-established healthcare systems and growing demand for injectable therapies. The strong regulatory focus on patient and healthcare worker safety is also driving the sales of hypodermic needles. The increasing prevalence of chronic diseases is further boosting the application of hypodermic needles.
The Germany hypodermic needles market is estimated to be valued at USD 444.01 million by 2036. The country’s advanced healthcare infrastructure and strong medical device industry are propelling the sales of hypodermic needles. The rising surgical procedures and chronic disorders are fueling the application of hypodermic needles. Statistisches Bundesamt reports that there were 16,531,491 surgeries performed on fully admitted hospital patients in 2023.
The UK hypodermic needles market for hypodermic needles is set to expand at a CAGR of 5.38% during the forecast period. The increasing prevalence of chronic diseases and continuous investment in modern healthcare services are fueling the trade of hypodermic needles. The high volume of vaccinations and diagnostic procedures also contributes to the overall hypodermic needles market growth.
Key Hypodermic Needles Market Players:
- B. Braun SE (Germany)
- BD (U.S.)
- Cardinal Health (U.S.)
- Connecticut Hypodermics Inc. (U.S.)
- Exelint International, Co. (U.S.)
- Henke Sass Wolf (Germany)
- Hi-Tech Syringes (India)
- ICU Medical, Inc. (U.S.)
- Nipro Europe Group Companies (Belgium)
- Retractable Technologies, Inc. (U.S.)
- Terumo Medical Corporation (Japan)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- B. Braun SE is a global healthcare and medical technology company dedicated to enhancing patient care through a comprehensive portfolio of medical products and therapeutic solutions. The company designs, manufactures, and supplies medical devices, pharmaceuticals, and healthcare systems used across hospitals, ambulatory care, and home healthcare settings. Its broad product offering includes infusion therapy, surgical instruments, dialysis technologies, and infection prevention solutions, enabling safe and efficient treatment across a wide range of clinical specialties.
- BD is a global medical technology company that supports healthcare delivery through an extensive portfolio of diagnostic, medical device, and interventional solutions. The company focuses on improving patient care by integrating technologies that enhance clinical workflows, support informed decision-making, and optimize treatment outcomes. Serving hospitals, laboratories, research institutions, and healthcare providers worldwide, BD plays a vital role in advancing disease diagnosis, laboratory efficiency, and safe clinical practices through continuous innovation.
- Cardinal Health is a global healthcare services and products company that supports the delivery of medical products and pharmaceuticals throughout the healthcare supply chain. In addition to manufacturing selected medical products, the company specializes in distribution, logistics, inventory management, and technology-enabled healthcare solutions that connect manufacturers, providers, and patients. Its diversified business portfolio includes pharmaceutical distribution, medical and surgical products, nuclear pharmacy services, and home healthcare solutions, helping improve operational efficiency across the continuum of care.
- Connecticut Hypodermics Inc. is a specialized manufacturer focused on precision-engineered hypodermic needles and custom tubular components for medical and industrial applications. The company emphasizes advanced manufacturing capabilities and engineering expertise to deliver highly customized solutions that meet stringent customer specifications. With a strong focus on precision fabrication, product consistency, and quality assurance, Connecticut Hypodermics supports medical device manufacturers through tailored production processes and innovative engineering solutions.
- Exelint International Co. is a medical device company engaged in the manufacturing and distribution of disposable medical products for healthcare and veterinary applications. Its product portfolio includes hypodermic needles, syringes, blood collection products, infusion devices, and other essential medical consumables designed to support routine clinical procedures. The company operates through an integrated manufacturing and distribution model, working with authorized partners to supply reliable, high-quality healthcare products across domestic and international markets.
Below is the list of the key players, among several others, operating in the global hypodermic needles market:
The strong presence of regional and international companies characterizes the hypodermic needles market. Leading companies are focused on technological innovations to introduce next-gen solutions. They are also engaging in strategic collaborations with others to enhance their product offerings. Some gigantic companies are exploring opportunities across high-potential economies to earn lucrative returns. Both organic and inorganic marketing strategies are projected to double the revenues of key players during the forecast period.
Corporate Landscape of the Global Hypodermic Needles Market:
Recent Developments
- In April 2026, BD (Becton, Dickinson and Company) announced the launch of the BD CentroVena One Insertion System, the first all-in-one device for placing a central venous catheter. It is designed to make central line insertion easier for clinicians and improve patient safety through a simpler, more efficient process in critical care settings.
- In January 2026, Terumo Medical Corporation announced the launch of its SurTract Safety Syringe in the United States. Built with SafeR passive safety technology, it will be supplied to hospitals, clinics, and emergency care centers from the first quarter of 2026.
- Report ID: 4914
- Published Date: Jul 16, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
About this Report
Connect with our Expert
Report, 2027-2036
Copyright @ 2026 Research Nester. All Rights Reserved.
